PassionBio accelerates drug development and transforms pharma assets through an active investment approach. The company is built around leading former BioNTech executives with backgrounds from major pharma organizations including Sanofi, GSK, Johnson & Johnson, and Takeda, combined with experience in investment structuring and fund management. We target programs where we can shape or redesign the clinical plan to achieve faster timelines, clinically meaningful benefit, and real-world health impact over the standard-of-care at the time of launch. We engage hands-on through operational work and direct involvement in clinical plan design, drawing on our expertise and global network. PassionBio Capital, a registered EuVECA fund incorporated in February 2026, serves as the dedicated investment vehicle.